A list that might be interesting only to me, but I will share anyway: The biotech and drug stocks getting hit the hardest during the biotech correction -- or whatever you want to call it:
Geron shares slid following the FDA's decision to place its lead drug imetelstat on clinical hold due to safety concerns, so it's not fair to blame the market weakness in March for its woes.
A trio of stocks tied in third place: Xoma (XOMA) - Get XOMA Corporation Report, Cytrx (CYTR) and Celldex Therapeutics (CLDX) - Get Celldex Therapeutics, Inc. Report have all lost 39% of their value in March.
Cytrx's entanglement in a messy stock promotion scandal with the specter of an SEC investigation hovering of the stock easily explains the sell off. Xoma also issued some negative clinical data early in the month.
Celldex is a bit tougher to figure out.
Celldex has benefitted from inclusion in the "immuno-oncology" investing craze, so perhaps the selling we're seeing here is an unwinding of a biotech buzzword trade.
NewLink is another over-valued cancer buzzword stock which is finally reverting back to the mean. Raptor is proof that orphan-drug disease stocks aren't all gravity proof, especially when you provide disappointing 2014 sales guidance.
Other notably weak biotech and drug stocks in March: Agenus (AGEN) - Get Agenus Inc. Report (-33%), Galena Biopharma (GALE) (-32%), Zogenix (ZGNX) - Get Zogenix, Inc. Report (-32%), Novavax (NVAX) - Get Novavax, Inc. Report (-34%) and Oramed Pharmaceuticals (ORMP) - Get Oramed Pharmaceuticals Inc. Report (-27%). The reasons for weakness in most of these should be self-evident.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.